Molecular Characterization ofHelicobacter pyloriVacA Induction of IL-8 in U937 Cells Reveals a Prominent Role for p38MAPK in Activating Transcription Factor-2, cAMP Response Element Binding Protein, and NF-κB Activation-Reference-Cited by-同舟云学术

Molecular Characterization ofHelicobacter pyloriVacA Induction of IL-8 in U937 Cells Reveals a Prominent Role for p38MAPK in Activating Transcription Factor-2, cAMP Response Element Binding Protein, and NF-κB Activation

Published:2008-03-19 Issue:7 Volume:180 Page:5017-5027
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Hisatsune Junzo,Nakayama Masaaki,Isomoto Hajime,Kurazono Hisao,Mukaida Naofumi,Mukhopadhyay Asish K.,Azuma Takeshi,Yamaoka Yoshio,Sap Jan,Yamasaki Eiki,Yahiro Kinnosuke,Moss Joel,Hirayama Toshiya

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference63 articles.

1. Living dangerously: how Helicobacter pylori survives in the human stomach

2. Helicobacter pylori and gastrointestinal tract adenocarcinomas

3. Persistent bacterial infections: the interface of the pathogen and the host immune system

4. Helicobacter pylori VacA, a paradigm for toxin multifunctionality

5. Helicobacter pylori virulence factors: facts and fantasies

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbial natural compounds and secondary metabolites as Immunomodulators: A review;International Journal of Biological Macromolecules;2024-10

2. Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation;Journal of Anesthesia and Translational Medicine;2024-06

3. Pathogenesis and potential reversibility of intestinal metaplasia − a milestone in gastric carcinogenesis;Radiology and Oncology;2024-04-21

4. Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability;Immunity & Ageing;2024-01-02

5. Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression of ATF2;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-04